Evidence map›Paper›PMID 41567188›Full record

ReviewFrontiers in immunology2025

The pro-tumorigenic roles of granzyme B: mechanisms and therapeutic implications.

Yubi Zhang, Han Huang, Linjun Xie, Chunhong Li, Xiangyu Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yubi ZhangDepartment of Thyroid Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou Sichuan, China.
Han HuangDepartment of Thyroid Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou Sichuan, China.
Linjun XieDepartment of Thyroid Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou Sichuan, China.
Chunhong LiDepartment of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou Sichuan, China.
Xiangyu ZhouDepartment of Thyroid Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granzyme B (GZMB) is an effector molecule primarily expressed by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Historically, GZMB expression levels have served as a marker of immune activity, indicative of the potency of anti-tumor immunity. However, recent evidence increasingly demonstrates that GZMB also exerts immunosuppressive effects within the tumor microenvironment. Beyond CTLs and NK cells, GZMB derived from multiple immune and tumor cells promotes tumor initiation and progression by regulating biological processes such as extracellular matrix remodeling, epithelial-mesenchymal transition, and angiogenesis. This paper summarizes the pro-tumor sources and mechanisms of GZMB, providing a comprehensive understanding of its clinical significance to guide more holistic GZMB-based anti-tumor therapies.

Indexed as

GranzymesNeoplasmsAnimalsEpithelial-Mesenchymal TransitionExtracellular MatrixHumansKiller Cells, NaturalT-Lymphocytes, CytotoxicTumor MicroenvironmentGranzymesGZMB protein, humanepithelial-mesenchymal transition(EMT)extracellular matrix (ECM) remodelinggranzyme B(GZMB)pro-tumortumor microenvironment(TME)

Identifiers

PMID41567188
PMCPMC12816280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.